Facebook Outage Disrupts Thousands of Users Across the United States 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Malta will gain from smart heritage 
Rio Tinto Advances Gallium Extraction Project in Canada with Federal Funding Support 
Nvidia to Launch New AI Inference Processor to Boost OpenAI Performance 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Peter Mandelson Arrested in London Amid Jeffrey Epstein Ties Investigation 
Shell to Invest $667M in Brazil’s Struggling Sugar and Ethanol Producer Raizen 
Defense Contractors Move to Drop Anthropic AI After Trump Administration Ban 
AWS Data Centers in UAE and Bahrain Hit by Drone Strikes Amid Middle East Conflict 
JPMorgan Closes Trump Accounts as $5 Billion Lawsuit Moves to New York 
Democrats Pledge Major Spending on Virginia Redistricting Ahead of Midterm Elections 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
United Airlines Boeing 787-9 Makes Emergency Landing in Los Angeles After Possible Engine Fire 
Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology used in its COVID-19 vaccine. The agreement resolves multiple lawsuits accusing Moderna of using the companies’ LNP delivery system without authorization in its mRNA-based vaccine.
Under the terms of the settlement, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion may be paid depending on the outcome of a separate legal appeal. The deal brings closure to both U.S. and international legal actions related to the disputed vaccine technology.
Lipid nanoparticles play a critical role in mRNA vaccines, including Moderna’s COVID-19 shot. The technology acts as a protective carrier that shields fragile messenger RNA molecules and helps deliver them safely into human cells, enabling the vaccine to trigger an immune response. Genevant and Arbutus claimed ownership of key patents covering this LNP delivery system and argued that Moderna used the technology without proper licensing.
As part of the settlement, Moderna stated it will not owe royalties to Genevant or Arbutus for LNP technology in its future vaccine products. This clause removes potential financial uncertainty for the biotech company as it continues developing new vaccines, including updated COVID-19 shots and combination COVID/flu vaccines.
Investors reacted positively to the announcement. Moderna shares surged more than 10% in after-hours trading following the news. Arbutus Biopharma stock climbed approximately 11%, while Roivant Sciences, Genevant’s parent company, saw a modest gain of about 1%.
Analysts believe the settlement removes a significant legal risk for Moderna. According to Jefferies analyst Andrew Tsai, the agreement eliminates the worst-case scenario of paying double-digit royalty rates on vaccine sales. Considering Moderna has generated roughly $48 billion in global COVID-19 vaccine revenue, the settlement amount represents only a small fraction of those earnings.
The case had been scheduled to go to trial in Delaware federal court, marking what would have been the first major trial among several high-stakes patent disputes tied to COVID-19 vaccine technology. Similar lawsuits involving Pfizer and BioNTech remain ongoing, highlighting the intense competition and intellectual property battles within the rapidly evolving mRNA vaccine industry.
